Meropenem Kabi

Meropenem Trihydrate, the active ingredient in Meropenem Kabi, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats severe bacterial infections, including intra‑abdominal, urinary, respiratory, and central nervous system infections, in hospitalized patients requiring parenteral therapy.

GNH USA supplies Meropenem Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat serious Gram‑negative and Gram‑positive bacterial infections.

- Complicated intra‑abdominal infections: provides rapid bacterial eradication and clinical cure. - Complicated urinary tract infections: eliminates resistant uropathogens and resolves infection. - Hospital‑acquired pneumonia, including ventilator‑associated pneumonia: achieves high lung tissue concentrations for effective treatment. - Bacterial meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections. - Sepsis and febrile neutropenia: offers broad coverage against multidrug‑resistant organisms.

Adverse reactions may occur with meropenem therapy and are categorized by frequency.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Headache: transient cranial discomfort. - Rash: mild skin erythema. - Elevated liver enzymes: transient increase in hepatic transaminases. - Phlebitis at infusion site: irritation of peripheral veins.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: particularly in patients with renal impairment or CNS disorders. - Clostridioides difficile colitis: severe intestinal infection. - Hemolytic anemia: rare destruction of red blood cells. - Acute kidney injury: sudden decline in renal function. - Stevens‑Johnson syndrome: severe mucocutaneous reaction.

When using Meropenem Kabi, clinicians should consider several safety measures.

- Renal function: adjust dose in patients with impaired kidney function. - Seizure risk: monitor patients with a history of epilepsy or CNS disorders. - Hypersensitivity: avoid in individuals with known carbapenem or β‑lactam allergy. - Pregnancy and lactation: use only if the potential benefit outweighs the risk. - Drug‑induced liver injury: monitor hepatic enzymes during prolonged therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medicines, requiring attention to the level of interaction.

Major Interactions (Avoid): - Valproic acid: may reduce antiepileptic effect and increase seizure risk. - Probenecid: can increase meropenem plasma concentrations, raising toxicity potential.

Moderate Interactions (Monitor Closely): - Aminoglycosides: concurrent use may enhance nephrotoxicity. - Loop diuretics: may increase risk of ototoxicity when combined with other ototoxic agents. - Anticoagulants (e.g., warfarin): monitor INR as meropenem may alter coagulation parameters.